Megace (Megestrol Acetate)

Megestrol acetate is a synthetic progestogen that binds to progesterone receptors. This binding produces antineoplastic effects by inhibiting hormone‑driven tumor proliferation and exerts glucocorticoid‑like activity that increases appetite and alters metabolism, leading to weight gain.

The dose of Megace is individualized by the prescribing clinician based on the patient’s condition, severity of cachexia, and overall treatment plan. Dosage may vary widely, and the prescriber determines the appropriate strength and schedule for each case.

Safety data for Megace in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Megace, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Megace is often compared with corticosteroids such as dexamethasone, which also stimulate appetite. While both can increase weight, Megace provides additional antineoplastic hormone activity useful in certain cancers, whereas steroids have broader anti‑inflammatory effects but may carry a different side‑effect profile.

Megace tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in a refrigerator or freezer, and keep out of reach of children.

Megace is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should follow the prescribing clinician’s instructions for timing and frequency.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, adrenal insufficiency due to cortisol suppression, and severe hyperglycemia that may require medical intervention. Patients should seek immediate medical attention if they experience unexplained swelling, shortness of breath, or signs of infection.

Megace should not be used by individuals with known hypersensitivity to megestrol acetate or any tablet excipients, those with active thromboembolic disease, uncontrolled diabetes, or severe hepatic impairment. Pregnant women should avoid it unless clearly indicated, and it is contraindicated in patients requiring anticoagulation without close monitoring.